Author: NORML

Cannabis Excelsior: Remembering Doug Greene

Doug was a passionate advocate for ending America’s failed war on cannabis consumers, and his work with NORML and for the cause spans decades not years. This is a sad loss for his friends and family, the New York cannabis community, and the legalization movement.

FDA Hearing On ‘Hemp-Derived CBD’ Today

In its written testimony, NORML Deputy Director Paul Armentano encourages the agency to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.

Clinical Trial: CBD Administration Reduces Heroin Cravings

The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. Commenting on the study’s findings, NORML Deputy Director Paul Armentano said, “These conclusions add to the growing body of evidence that cannabis and its constituents represent an exit away from the use or abuse of other controlled substances rather than a supposed ‘gateway.'”